Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| macrophage | 23 studies | 29% ± 16% | |
| ciliated cell | 11 studies | 26% ± 7% | |
| epithelial cell | 6 studies | 32% ± 10% | |
| myeloid cell | 6 studies | 35% ± 16% | |
| monocyte | 5 studies | 26% ± 9% | |
| basal cell | 5 studies | 28% ± 10% | |
| enterocyte | 4 studies | 24% ± 4% | |
| secretory cell | 3 studies | 25% ± 9% | |
| mononuclear phagocyte | 3 studies | 31% ± 17% | |
| classical monocyte | 3 studies | 43% ± 35% | |
| dendritic cell | 3 studies | 25% ± 9% | |
| non-classical monocyte | 3 studies | 31% ± 17% | |
| goblet cell | 3 studies | 21% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| intestine | 4 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 2089.76 | 245 / 245 | 100% | 177.45 | 502 / 502 |
| thymus | 100% | 3611.14 | 653 / 653 | 100% | 302.82 | 604 / 605 |
| kidney | 100% | 2794.56 | 89 / 89 | 100% | 157.00 | 898 / 901 |
| stomach | 100% | 1940.81 | 359 / 359 | 100% | 118.13 | 285 / 286 |
| intestine | 100% | 3529.28 | 964 / 966 | 99% | 125.31 | 523 / 527 |
| ovary | 100% | 1658.61 | 180 / 180 | 99% | 72.87 | 424 / 430 |
| liver | 100% | 1873.20 | 226 / 226 | 98% | 105.37 | 399 / 406 |
| lung | 99% | 2133.30 | 574 / 578 | 99% | 138.05 | 1143 / 1155 |
| pancreas | 99% | 1064.28 | 325 / 328 | 98% | 128.64 | 175 / 178 |
| breast | 100% | 1537.54 | 458 / 459 | 97% | 105.57 | 1085 / 1118 |
| bladder | 100% | 2423.62 | 21 / 21 | 97% | 133.10 | 487 / 504 |
| uterus | 100% | 1511.52 | 170 / 170 | 94% | 87.00 | 430 / 459 |
| adrenal gland | 100% | 2616.20 | 258 / 258 | 93% | 66.87 | 215 / 230 |
| esophagus | 99% | 1136.51 | 1433 / 1445 | 84% | 64.70 | 153 / 183 |
| skin | 79% | 764.48 | 1437 / 1809 | 92% | 89.28 | 432 / 472 |
| brain | 87% | 567.31 | 2294 / 2642 | 60% | 30.99 | 423 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 337.65 | 29 / 29 |
| spleen | 100% | 3537.72 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 62.09 | 1 / 1 |
| adipose | 100% | 1888.38 | 1202 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2056.01 | 1329 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 71.72 | 41 / 45 |
| muscle | 90% | 664.25 | 725 / 803 | 0% | 0 | 0 / 0 |
| heart | 89% | 755.42 | 765 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 85% | 1229.02 | 794 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 74% | 44.20 | 59 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0016139 | Biological process | glycoside catabolic process |
| GO_0019377 | Biological process | glycolipid catabolic process |
| GO_0006004 | Biological process | fucose metabolic process |
| GO_0006027 | Biological process | glycosaminoglycan catabolic process |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0035578 | Cellular component | azurophil granule lumen |
| GO_0043202 | Cellular component | lysosomal lumen |
| GO_0005764 | Cellular component | lysosome |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0004560 | Molecular function | alpha-L-fucosidase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FUCA1 |
| Protein name | Tissue alpha-L-fucosidase (EC 3.2.1.51) (Alpha-L-fucosidase I) (Alpha-L-fucoside fucohydrolase 1) (Alpha-L-fucosidase 1) |
| Synonyms | Nbla10230 |
| Description | FUNCTION: Alpha-L-fucosidase is responsible for hydrolyzing the alpha-1,6-linked fucose joined to the reducing-end N-acetylglucosamine of the carbohydrate moieties of glycoproteins. . |
| Accessions | P04066 ENST00000374479.4 |